

Dineika Chandrananda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6623198/publications.pdf>

Version: 2024-02-01

15
papers

1,547
citations

687363

13
h-index

1058476

14
g-index

21
all docs

21
docs citations

21
times ranked

2865
citing authors

#	ARTICLE	IF	CITATIONS
1	Refined characterization of circulating tumor DNA through biological feature integration. Scientific Reports, 2022, 12, 1928.	3.3	18
2	Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA. Genome Research, 2022, 32, 215-227.	5.5	41
3	Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. EMBO Molecular Medicine, 2021, 13, e12881.	6.9	61
4	Custom workflows to improve joint variant calling from multiple related tumour samples: FreeBayesSomatic and Strelka2Pass. Bioinformatics, 2021, , .	4.1	0
5	ctDNA monitoring using patient-specific sequencing and integration of variant reads. Science Translational Medicine, 2020, 12, .	12.4	116
6	Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. Genome Medicine, 2020, 12, 23.	8.2	66
7	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients – initial observations. PLoS ONE, 2020, 15, e0231884.	2.5	11
8	Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models. Cancer Research, 2019, 79, 220-230.	0.9	67
9	Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. EMBO Molecular Medicine, 2018, 10, .	6.9	123
10	Enhanced detection of circulating tumor DNA by fragment size analysis. Science Translational Medicine, 2018, 10, .	12.4	670
11	Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients. Journal of Molecular Diagnostics, 2018, 20, 883-892.	2.8	81
12	Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer. EMBO Molecular Medicine, 2018, 10, .	6.9	61
13	Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. Scientific Reports, 2017, 7, 5554.	3.3	73
14	High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA. BMC Medical Genomics, 2015, 8, 29.	1.5	107
15	Investigating and Correcting Plasma DNA Sequencing Coverage Bias to Enhance Aneuploidy Discovery. PLoS ONE, 2014, 9, e86993.	2.5	24